BetterLife Pharma Inc.

CNSX: BETR


Canadian symbol: BETR.CN
US symbol: BETRF

Currency in CAD

Valuation Measures

Market Cap (intraday) 539.49M
Enterprise Value 330.74M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)10.31
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7-4.77

Trading Information

Stock Price History

Beta (5Y Monthly) 2.10
52-Week Change 3-76.00%
S&P500 52-Week Change 343.61%
52 Week High 32.9000
52 Week Low 30.4300
50-Day Moving Average 30.8371
200-Day Moving Average 31.1577

Share Statistics

Avg Vol (3 month) 373.84k
Avg Vol (10 day) 383.21k
Shares Outstanding 559.83M
Implied Shares Outstanding 6N/A
Float 41.85M
% Held by Insiders 116.33%
% Held by Institutions 10.34%
Shares Short (Apr. 14, 2021) 4722.18k
Short Ratio (Apr. 14, 2021) 411.45
Short % of Float (Apr. 14, 2021) 41.51%
Short % of Shares Outstanding (Apr. 14, 2021) 41.43%
Shares Short (prior month Mar. 14, 2021) 4539.85k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Jun. 25, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Jan. 30, 2020
Most Recent Quarter (mrq)Oct. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-29.43%
Return on Equity (ttm)-230.52%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-85.9k
EBITDA -6.45M
Net Income Avi to Common (ttm)-19.52M
Diluted EPS (ttm)-0.9600
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)518.44k
Total Cash Per Share (mrq)0.01
Total Debt (mrq)4.07M
Total Debt/Equity (mrq)171.47
Current Ratio (mrq)0.17
Book Value Per Share (mrq)0.06

Cash Flow Statement

Operating Cash Flow (ttm)-6.03M
Levered Free Cash Flow (ttm)2.46M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
16.33%% of Shares Held by All Insider
0.34%% of Shares Held by Institutions
0.41%% of Float Held by Institutions
1Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by BetterLife Pharma Inc.


BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs

VANCOUVER, British Columbia, April 29, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has applied for patent protection of its ... Read More...

Geodrill Provides Notice of 2020 Fourth Quarter and Year-End Financial Results and Conference Call

VANCOUVER, BC, Dec. 7, 2020 - The following issues have been halted by IIROC:Company: BetterLife Pharma Inc.CSE Symbol: BETRAll Issues: NoReason: At the request of the Company Pending NewsHalt Time (ET): 2:05 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ... Read More...

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

VANCOUVER, Jan. 27, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for ... Read More...

BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases

VANCOUVER, Jan. 26, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, today announced it has confirmed stability of its inhalable interferon ... Read More...

BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia

VANCOUVER, Jan. 21, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that it has engaged Equilab International to manage the ... Read More...

BetterLife Announces Formation of Next Generation Psychedelic Research Advisory Board

VANCOUVER, Jan. 07, 2021 -- January 7, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce the formation of its Next Generation Psychedelic Research Advisory Board and appointment of highly experienced Ms. Hattie Wells as its first member... Read More...

BetterLife Pharma Strengthens Board of Directors

VANCOUVER, Dec. 28, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in psychedelic medicines. Mr. Stetsenko is a financier and venture cap... Read More...

BetterLife Welcomes Psychedelic Industry Leaders to the Senior Management Team

VANCOUVER, Dec. 22, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined the Company. Mr. Kroupa and Mr. Kirkland will join the senior ma... Read More...

BetterLife Closes Acquisition of Second Generation Psychedelic Assets of Transcend Biodynamics LLC

VANCOUVER, Dec. 20, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) is pleased to announce that further to its press release of December 8, 2020, the Company has completed its acquisition to acquire 100% of the assets in Transcend Biodynamics LLC (“Transcend”) in an all-stock transacti... Read More...

BetterLife’s Recent Acquisition: Taking LSD from Experimental to a Major Therapeutic Application

VANCOUVER, Dec. 14, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting edge treatments, today announced the value proposition of its acquisition of Transcend Biodynamics, LLC’s (“Transcend”) manufacturing pat... Read More...

Pre-IND Discussion with U.S. FDA Helps BetterLife Set Up AP-003 Clinical Trials in Australia

VANCOUVER, Nov. 10, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company focused on development and commercialization of interferon based treatments, today announced a clinical and regulatory update for its AP-003 COVID-19 clinical trials following discussions wi... Read More...

BetterLife Pharma Signs eTMF Partner to Help Accelerate AP-003 Clinical Trial Operations

VANCOUVER, Nov. 04, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company that is beginning clinical trials of AP-003, its COVID-19 inhalation therapeutic, announced today that it has selected Florence Healthcare to provide its electronic Trial Master File (‘eTMF’... Read More...

UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon Beta

NEW YORK CITY, Oct. 28, 2020 -- UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon BetaThe Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing for clinical trials of AP-003, its interfer... Read More...

BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Other Treatements

New York City, Oct. 27, 2020 -- The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing for clinical trials of AP-003, its interferon alpha 2b COVID-19 treatment, joined investor portal Proactive to discuss the key differences between the interferon inhalation ... Read More...

Betterlife Pharma Announces Up To $5.0 Million Private Placement Offering Of Special Warrants

VANCOUVER, Oct. 19, 2020 -- NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATESBetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT), an emerging biotech company, is pleas... Read More...

BetterLife Pharma Receives Approval from Altum Pharmaceuticals Inc. Shareholders to Complete Merger

Vancouver, July 30, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotechnology company with proprietary interferon-based therapeutic technologies, is pleased to provide an update on the results of the Special Meeting of the shareholders of Altum Pharmaceuticals Inc. (“A... Read More...

BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan

VANCOUVER, BC, July 27, 2020 - BetterLife Pharma Inc. ("BetterLife") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) is pleased to provide an update on the proposed acquisition of Altum Pharmaceuticals Inc. ("Altum") and its upcoming clinical programs. A Special Meeting of Altum shareholders, more than 72% of whom have signed a Lock Up Agreement, ... Read More...

BetterLife CEO Discusses Merger, Planned Interferon Treatment Trials and Potential Subsequent FDA Emergency Use Authorization

New York City, July 23, 2020 -- The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRD) (CSE:BETR), an emerging biotechnology company currently preparing its own interferon-based coronavirus treatment clinical trials, recently joined online portal Proactive for a Q&A which included the upcoming merger with Altum Pharmaceu... Read More...

BetterLife (OTCQB:BETRD) Launches Website Emphasizing 3 Potentially Ground Breaking Treatments

Welcome to BLife TherapeuticsNew York City, July 14, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE:BETR) (OTCQB:BETRD) (FRA: BLife Therapeutics BLife TherapeuticsNPAT) indicated the finalisation of its rebranding exercise for its wholly owned subsidiary, BLife Therapeutics, which has been publicly formalised through ... Read More...

BetterLife Pharma (OTCB:BETRD) CEO Discusses Using Interferons to Defeat ‘Truly Evil Virus’

New York City, July 06, 2020 -- The CEO of BetterLife Pharma (BETRD) (BETR.CN) (NPAT.F), an emerging clinical stage pharmaceutical development company, recently discussed the use of interferon therapy for COVID-19 with Alex Keown of BioSpace.Highlights of the interview include:BetterLife CEO Dr. Ahmad Doroudian noting that the coronavirus... Read More...

BetterLife Pharma (OTCQB:BETRD) Believe Inhalation Device Containing Proprietary Interferon May Fight Off COVID-19

New York, June 30, 2020 -- BetterLife Pharma (BETRD) (BETR.CN) (NPAT.F), an emerging clinical stage pharmaceutical development company, believe that a coronavirus inhaler therapeutic may hold the key to helping patients fight off symptoms of coronavirus as soon as symptoms start. In a trial planned for later this summer, the company inten... Read More...

BetterLife Pharma (OTCQB:BETRF) Looks to Immune Response Drug Interferon a2b as Potential Therapeutic for COVID-19

New York City, June 19, 2020 -- BetterLife Pharma (BETRF) (BETR.CN) (NPAT.F), an emerging clinical stage pharmaceutical development company, announced recently that it is exploring the potential of using a patent-pending proprietary interferon a2b (IFN a2b) inhalation formulation as a novel treatment for COVID-19, also known as the corona... Read More...

BetterLife Pharma Announces Appointment of Dr. Eleanor Fish, a leading expert on interferon activity against Covid-19, to its Advisory Board

VANCOUVER , May 19, 2020 - BetterLife Pharma Inc. ("BetterLife") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has appointed Dr. Eleanor Fish to the Company's Scientific Advisory Board. Dr. Fish is an accomplished scientist with focus on interferon activity against variety of viruses including Covid-19, SARA, Ebola and Zi... Read More...

BetterLife Pharma announces release of exploratory study on treatment of Covid-19 patients in Wuhan with Interferon

VANCOUVER , May 15, 2020 - BetterLife Pharma Inc. ("BetterLife") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that the journal Frontiers of Immunology ("Frontiers") released the results of the exploratory study on Treatment on a cohort of confirmed COVID-19 cases in Wuhan . The study can be found at https://www.frontiersin.org/a... Read More...

BetterLife Pharma announces Interferon Alpha-2b Covid-19 news regarding its emergence as a potential treatment for COVID-19

VANCOUVER , May 13, 2020 - BetterLife Pharma Inc. ("BetterLife") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that a third party study is scheduled to be released this Friday in the journal Frontiers of Immunology. The study investigated the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19 and found that... Read More...

BetterLife Pharma Confirms Re-Pricing of Warrants

VANCOUVER , May 12, 2020 - BetterLife Pharma Inc. ("BetterLife") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) confirms the re-pricing of warrants issued pursuant to financings completed in 2019 as announced in the Company's press release dated May 7 , 2020.The following warrants have been amended to have an exercise price of $0.25 per warrant:1... Read More...
Coming Soon.

Delayed data (1h)
NameAgePositionAppointed
Krisztian Toth
Executive Chairman of the Board
--Executive Chairman of the Board2019
Russell Nelles Starr
President
--President2019
Toni Rinow
Chief Executive Officer
--Chief Executive Officer2019
Moira Wi Ting Ong
Chief Financial Officer
41Chief Financial Officer2010
Chris Lucky
Chief Operating Officer
--Chief Operating Officer2019
Wolfgang Renz
Regional Manager Europe, Chief Medical Officer, Director
47Regional Manager Europe, Chief Medical Officer, Director2019
Joseph Borovsky
Director
--Director2019
Ken Kessler
Director
--Director2019


Share this page